PEER-REVIEW | DERMATOLOGY |
GENE EXPRESSION LEVELS IN ATHEROSCLEROSIS AND PSORIASIS
V.V Sobolev, M.E Sautin, E.S Piruzian, I.M Korsunskaya, A.V Melerzanov, O.A
Svitich, A.A Lavrov, and A.L Piruzyan present the findings from their
comparative study on the gene expression levels
for IL-17 in psoriasis and atherosclerosis patients
ABSTRACT With the help of real-time polymerase chain reaction the comparative analysis of gene expression levels for interleukin-17 (IL-17) in visually unaffected skin and psoriatic lesions, and in atherosclerotic affected vessels and unaffected parts of the femoral artery were
A atherosclerosis1,2 34 August/September 2015 |
prime-journal.com THEROSCLEROSIS
evaluated. The results showed a significant increase of gene expression for IL-17 in psoriasis and atherosclerosis. This may reflect the state of the pathological processes in psoriasis and atherosclerosis and be an indicator of the effectiveness of treatment at the molecular level.
IS A CHRONIC, PROGRESSIVE DISEASE
in which the arteries thicken and narrow as a result of the accumulation of fatty substances. Characterized by long-term and asymptomatic progression, atherosclerosis is a major mortality risk in developed countries. According to the references, inflammation is the key factor in the development of and psoriasis3
. Psoriasis is a chronic inflammatory skin condition characterized by typical
erythematous, scaly skin lesions, hyperproliferation of epidermal cells, acanthosis, inflammation in the dermis, and often associated with systemic manifestations. The etiology includes genetic and environmental factors4
. Research data points toward a possible association between psoriasis and
atherosclerosis. Patients with psoriasis without cardiovascular risk factors or clinically evident cardiovascular disease have a high prevalence of atherosclerosis5
.
Owing to the similarities between psoriasis and atherosclerosis, it is possible to investigate the molecular and genetic changes involved in both diseases.
Interleukin–17 Interleukin–17 (IL–17) is a cytokine that acts as a potent mediator in delayed-type reactions by increasing chemokine production in tissues in order to recruit monocytes and neutrophils to the site of inflammation. IL-17 is produced by Th17 cells, and results in destructive tissue damage in delayed-type reactions. The IL-17 cytokine family includes six members: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. IL-17A is often referred to as simply ‘IL–17’ and is an important proinflammatory cytokine with a critical role
IL-17
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64